Related Experiment Video
Updated: Jun 13, 2025
14:55
Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
Published on: April 18, 2011
13.7K
Pharmacologic Therapy for Spinal Cord Injury
Brandon A Sherrod1, Ken Porche1, Chad K Condie2
1Departments of Neurosurgery.
Clinical Spine Surgery
|September 12, 2024
Summary
Few drugs effectively treat acute spinal cord injury (SCI) by preventing secondary injury. Research reviews current pharmacologic options and ongoing trials, seeking better neuroprotective strategies for improved outcomes.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Research
Background:
- Acute spinal cord injury (SCI) research focuses on preventing secondary neurologic damage.
- Understanding primary and secondary injury mechanisms has advanced, yet few drugs improve outcomes in clinical trials.
Purpose of the Study:
- To review pharmacologic therapies for acute SCI.
- To discuss treatments for secondary SCI effects and current clinical trials.
Main Methods:
- Literature review of existing studies and clinical guidelines.
- Analysis of pharmacologic agents like corticosteroids, GM-1 ganglioside, Riluzole, and others.
- Review of ongoing clinical trials for pharmacotherapy and cellular transplantation.
Main Results:
- Few pharmacologic agents have demonstrated consistent efficacy in large trials for acute SCI.
- Vasopressors for mean arterial pressure augmentation and bradycardia management are discussed.
Conclusions:
- Current evidence for clinically beneficial post-SCI pharmacotherapy is limited.
- Future research is crucial to identify effective therapeutic agents for improving neurologic function after SCI.
Related Concept Videos
01:29Spasmolytic Agents: Chemical Classification
871
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
871
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398
01:29Drug Delivery: Parenteral Route
445
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
445
01:24Centrally Acting Muscle Relaxants: Therapeutic Uses
644
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
644